drugset / Trial / NCT01995370

Cilostazol Stroke Prevention Study for Antiplatelet Combination

NCT01995370

RandomizedParallel-groupOpen-labelPrevention

Summary

To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in high-risk patients for stroke

Timeline

Start
2013-12-13
Primary completion
2018-12-07
Completion
2018-12-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 81 mg Oral
Subject Aspirin Small molecule 100 mg Oral
Subject Cilostazol Small molecule 100 mg Oral
Subject Clopidogrel Small molecule 50 mg Oral
Subject Clopidogrel Small molecule 75 mg Oral

Indications